1) 「胃癌治療ガイドライン 医師用2018年1月改訂 第5版」(日本胃癌学会/編), 金原出版, 2018
2) Sasako M, et al:Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol, 29:4387-4393, 2011
3) Bang YJ, et al:Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):a phase 3 open-label, randomised controlled trial. Lancet, 379:315-321, 2012
4) Fuchs CS, et al:Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD):an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 383:31-39, 2014
5) Shitara K, et al:Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer(ABSOLUTE):an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol, 2:277-287, 2017
6) Kang YK, et al:Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATTRACTION-2):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 390:2461-2471, 2017